Artemis Investment Management LLP Has $13.31 Million Stake in EXACT Sciences Co. (NASDAQ:EXAS)

Artemis Investment Management LLP decreased its holdings in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 147,529 shares of the medical research company’s stock after selling 1,946 shares during the quarter. Artemis Investment Management LLP owned 0.11% of EXACT Sciences worth $13,313,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Sheaff Brock Investment Advisors LLC increased its stake in shares of EXACT Sciences by 1.8% in the third quarter. Sheaff Brock Investment Advisors LLC now owns 6,900 shares of the medical research company’s stock valued at $624,000 after buying an additional 125 shares during the period. Shine Investment Advisory Services Inc. increased its stake in shares of EXACT Sciences by 31.8% in the third quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock valued at $47,000 after buying an additional 125 shares during the period. Strs Ohio increased its stake in shares of EXACT Sciences by 0.3% in the third quarter. Strs Ohio now owns 66,784 shares of the medical research company’s stock valued at $6,035,000 after buying an additional 200 shares during the period. Kovack Advisors Inc. increased its stake in shares of EXACT Sciences by 10.4% in the third quarter. Kovack Advisors Inc. now owns 2,485 shares of the medical research company’s stock valued at $225,000 after buying an additional 235 shares during the period. Finally, Coastal Investment Advisors Inc. increased its stake in shares of EXACT Sciences by 65.7% in the third quarter. Coastal Investment Advisors Inc. now owns 648 shares of the medical research company’s stock valued at $59,000 after buying an additional 257 shares during the period. 86.59% of the stock is owned by institutional investors.

EXAS has been the subject of several recent research reports. Leerink Swann lowered their price objective on EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Friday, January 10th. ValuEngine downgraded EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. BTIG Research initiated coverage on EXACT Sciences in a research note on Friday, January 10th. They issued a “buy” rating and a $127.00 price objective for the company. Finally, Citigroup initiated coverage on EXACT Sciences in a research note on Monday, January 6th. They issued a “buy” rating and a $120.00 price objective for the company. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. EXACT Sciences has an average rating of “Buy” and an average price target of $122.06.

In other EXACT Sciences news, insider G Bradley Cole sold 28,016 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $80.38, for a total transaction of $2,251,926.08. Following the completion of the sale, the insider now owns 30,987 shares of the company’s stock, valued at approximately $2,490,735.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.20% of the company’s stock.

NASDAQ:EXAS opened at $93.00 on Wednesday. The company has a market capitalization of $13.56 billion, a PE ratio of -68.38 and a beta of 1.35. The company has a 50 day simple moving average of $91.35 and a two-hundred day simple moving average of $101.22. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.63 and a current ratio of 2.75. EXACT Sciences Co. has a fifty-two week low of $73.63 and a fifty-two week high of $123.99.

EXACT Sciences (NASDAQ:EXAS) last released its earnings results on Tuesday, October 29th. The medical research company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. The business had revenue of $218.81 million during the quarter, compared to the consensus estimate of $216.14 million. EXACT Sciences had a negative net margin of 29.83% and a negative return on equity of 29.06%. The company’s revenue for the quarter was up 85.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.37) EPS. Research analysts predict that EXACT Sciences Co. will post -1.63 EPS for the current year.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: How to start trading in the forex market?

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply